Meeder Advisory Services Inc. Purchases 133 Shares of Stryker Co. (NYSE:SYK)

Meeder Advisory Services Inc. grew its position in shares of Stryker Co. (NYSE:SYK) by 1.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,883 shares of the medical technology company’s stock after purchasing an additional 133 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Stryker were worth $3,198,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Stryker during the fourth quarter worth approximately $25,000. Dunhill Financial LLC grew its holdings in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the last quarter. Rakuten Securities Inc. raised its position in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC bought a new stake in Stryker in the fourth quarter worth $30,000. Finally, BankPlus Trust Department purchased a new stake in Stryker during the fourth quarter valued at about $33,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Up 0.3 %

Shares of Stryker stock opened at $373.20 on Wednesday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm has a market cap of $142.45 billion, a price-to-earnings ratio of 48.09, a PEG ratio of 2.93 and a beta of 0.95. The company has a 50-day moving average of $383.41 and a 200 day moving average of $374.43. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business earned $3.46 earnings per share. As a group, sell-side analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.90%. Stryker’s payout ratio is presently 43.30%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wells Fargo & Company lifted their price objective on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Stifel Nicolaus boosted their price objective on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Needham & Company LLC restated a “buy” rating and issued a $442.00 target price on shares of Stryker in a report on Friday, March 21st. Barclays upped their price target on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Finally, Citigroup reissued a “buy” rating and issued a $450.00 price target on shares of Stryker in a report on Wednesday, February 26th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.